RT info:eu-repo/semantics/article
T1 Treatment of primary nummular headache: a series of 183 patients from the NUMITOR study
A1 García Iglesias, Cristina
A1 Puledda, Francesca
A1 Echavarría Íñiguez, Ana
A1 González Osorio, Yesica
A1 Sierra Mencía, Álvaro
A1 Recio García, Andrea
A1 González Celestino, Ana
A1 Valle Peñacoba, Gonzalo
A1 Irimia, Pablo
A1 Guerrero Peral, Angel Luis
A1 García Azorín, David
K1 Headache
K1 Cefalea
K1 Headache - Treatment
K1 Cefalea - Tratamiento
K1 Head - Diseases
K1 Cabeza - Enfermedades
K1 Nervous system - Diseases - Treatment
K1 Nervioso, Sistema - Enfermedades - Tratamiento
K1 Medicine
K1 Neurology
K1 32 Ciencias Médicas
K1 3205.07 Neurología
AB Nummular headache (NH) is a primary headache characterized by superficial coin-shaped pain. NUMITOR (NCT 05475769) is an observational study evaluating the responder rate of preventive drugs in NH patients. The treatment response was assessed between weeks 8 and 12 compared with the baseline. Patients were included between February 2002 and October 2022. Demographic and clinical variables were assessed; treatment response was estimated by 50%, 30%, and 75% responder rates and treatment discontinuation due to inadequate tolerability. A total of 183 out of 282 patients fulfilled eligibility criteria and completed the study. Patients were aged 49.5 (standard deviation (SD): 16.8) years, and 60.7% were female. NH phenotype was a parietal circular pain of four centimeters’ diameter, moderate intensity, and oppressive quality. At baseline, patients had 25 (interquartile range) pain days per month. Preventive treatment was used by 114 (62.3%) patients. The highest 50% and 75% responder rates corresponded to onabotulinumtoxinA (62.5%, 47.5%), followed by gabapentin (43.7%, 35.2%). Oral preventive drugs were not tolerated by 12.9–25%. The present study provides class IV evidence of the effectiveness of oral preventive drugs and onabotulinumtoxinA in the treatment of primary NH. OnabotulinumtoxinA was the most effective and best-tolerated drug, positioning it as first-line treatment of NH.
PB MDPI
SN 2077-0383
YR 2022
FD 2022
LK https://uvadoc.uva.es/handle/10324/69587
UL https://uvadoc.uva.es/handle/10324/69587
LA eng
NO Journal of Clinical Medicine, 2023, Vol. 12, Nº. 1, 122
NO Producción Científica
DS UVaDOC
RD 12-sep-2024